Medical devices, healthcare technology and the business of care
510(k) clearance · K261203

multiFiltratePRO System

Fresenius Medical Care Renal Therapies Group, LLC · Decision date Oct 19, 2026

MEDTECHLEDGER EXPLANATIONK261203

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on 2026-10-19 for the multiFiltratePRO System, submitted by Fresenius Medical Care Renal Therapies Group, LLC of Waltham, Massachusetts. The application, K261203, was received on 04/13/2026 and is a Traditional 510(k) under regulation 876.5860, product code KDI, with the classification name Dialyzer, High Permeability With Or Without Sealed Dialysate System. The review panel and regulation medical specialty are listed as Gastroenterology/Urology.

SESE means the device was cleared as substantially equivalent to a predicate; it is not a PMA approval. The record lists clinical trial NCT05339139, no third-party review, no combination product status, and no authorized predetermined change control plan. The specific components, modifications, or indications described in the submission are not stated in the available record, so the scope of what was cleared beyond the device name and classification cannot be determined from these data.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 19, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K261203
Regulatory pathway
510(k) premarket notification
Product code
KDI
Decision code
SESE
Decision date
Oct 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Dialyzer, High Permeability With Or Without Sealed Dialysate System.

Product code
KDI
FDA device class
2

FDA decision timeline

  1. K261203 received

    Application receipt date recorded by FDA.

  2. K261203 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Fresenius Medical Care Renal Therapies Group, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Waltham, MA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records